M RGET RGET PTE 877 QUR SWSS VT PPE T BEUTY TS SUMMRY TBE First ines Global ction H concentration 20 mg/g 22 mg/g idocaine concentration eedle 30G 1/2 30G 1/2 27G 1/2 27G 1/2 27G 1/2 23G 1 ndications orrection of superficial wrinkles: fine lines and wrinkles on thin skin Filling of all moderately pronounced wrinkles on the full face Filling deep wrinkles njection area Papillary dermis Reticular dermis eep dermis Volume-creating capability H Y U R EFFETVE SFE G-STG eep dermis Subdermis or pre-periosteal Blister pack 2 x 0.7 m 2 x 1.2 m 1 x 3 m Estimated duration before touch up* 6 months up to 9 months 9 months up to 9 months 12 months up to 18 months when efficacy meets comfort * verage duration depends on several factors: patient's skin type, severity of the wrinkle to be corrected, type of injection and the volume injected. E PTM MFRT Hypodermis reation of volume (cheekbones, cheeks, chin, temporal area) es harmilles - Rue de yon, 105 - H 1203 Genève Tél. : +41 (0) 22 344 96 36 - Fax : +41 (0) 22 340 29 33 - Email : info@teoxane.com www.teoxane.com - www.teosyaltv.com REF : 500073/03 Harmonization of Redefinition of volume and lip facial contours contour orrection of very deep wrinkles in thick skin
RGET PTE 877 linically proven Results The most complete dermal fillers range with lidocaine the1st barrier Fear of pain QUR of patients towards injections METHGY Multicentrical study, r Trevidic and r laude (France, 2010) 32 patients 63% of patients type (Fitzpatrick skin scale) psos consumer study 2008 Split face design injection of nasolabial folds and lips with vs (, et ) ntense volume Pain assessment measured by VS* international scale The gentle way to give volume SGFT REUT F THE PTET'S P P SSESSEMET ips enhancement VS SE H Y U R EFFETVE SFE G-STG E 50 n-depth filling 40 PTM MFRT - 68,7% 30 Global ction Simplified filling PTET STSFT - 66,5% 20 «o pain» threshold reached after 5 min 10 First ines Soft lines 0 TESY BEFRE of patients injected with TESY are willing to be re-injected*. 1ml syringe injected asolabial folds, marionette lines 2x1ml syringes injected TESY 5 M FTER JET n-vitro test reproducing the action of oxidative stress in the skin When injected in the skin, hyaluronic acid gels suffer from a strong oxidative stress (skin inflammatory response) accelerating the % of remaining elasticity G 96 % deterioration of the product. 95 GRE 99% 1 MTH FTER oss of elasticity due to exposition to oxidative stress asolabial folds TESY n optimized durability 100% of patients injected satisfied by the aesthetic results of the treatment. GRE found injection significantly less painful than an injection without lidocaine*. GRE V 10 TESY URG JET mmediate and ong-lasting Results GRE V 9 patients out of (average perceived pain) 90 85 85 % Thanks to Teoxane aboratories know-how 80 in the conception of hyaluronic acid based 75 dermal fillers, 70 products offer a better protection against oxidative stress in comparison 65 60 55 52 % with other dermal fillers containing the same 50 H monophasic gel (H 24mg/ml + lidocaine 0,3%) H biphasic gel (H 20mg/ml + lidocaine 0,3%) concentration of lidocaine. (H 25mg/ml + lidocaine 0,3%) *Visual nalogic Scale * Multicentrical study done on 32 patients by octors Trevidic and laude, specialists in Plastic, Reconstructive and esthetics Surgery. 2010.
KSS EW FRMUT PTURE : R E PVÁ (Slovakia) PTURE : R E PVÁ (Slovakia) BEFRE FTER Excellent patient satisfaction: 94% would recommend a treatment with ew Formulation (1) 82% would do it again (1) Strong Resistance 40 High cohesivity for a long-lasting efficacy (2) specifically adapted to the mobility of the lips deal elastic profile for a smooth gel, easy and comfortable to inject under control Enhanced safety and tolerability for a delicate and highly exposed area Resistance to pressure and skin movements ohesivity (.s.) 30 20 10 0 EW FRMUT Solid 100 150 200 250 300 350 (1) Post-market clinical investigation on Teosyal ew Formulation made in ctober 2012 on 26 patients (women only, average age 41 years old) followed by 13 practitioners (2) urability from 9 to 12 months (3) eeded force to achieve a shape distortion (High modulus = hard to deform) G (Pa), at rest Elasticity modulus (3)
global approach to recover a natural smile! EW FRMUT Philtrum Redensity [ ] ermis redensification ip corners ips and lip contour Global ction / asolabial folds Marionnette lines TEXE T SURE EW FRMUT ip enhancement H concentration: 25 mg/ml idocaine: 0,3% (), Box: / eedle: 27G½" Redensity [ ] ermis redensification on cross-linked H concentration: 15 mg/ml idocaine 0,3% ermo-restructuring omplex* Box: & 1 x 3 m / eedle: 30G½" Global ction Simplified filling H concentration: 25 mg/ml idocaine: 0,3% (), Box: / eedle: 30G½" n-depth filling H concentration: 25 mg/ml idocaine: 0,3% (), Box: / eedle: 27G½" REF: 500214/01 EMHEU ESG SEPTEMBER 2013 (*) Patent pending
Pictures: r Kieren Bong, UK Pictures: r Kieren Bong, UK EW 2x1ml with a 27G½" needle BEFRE Easy to inject: lower extrusion force and more malleability for a better control of the injection with a 27G½" needle. Respect the depth of injection: subcutaneous and pre-periosteal High cohesivity: long-lasting effect over 18 months (2) Unique viscoelasticity: ideal remodeling gel dapted to your patients needs: less quantity for smaller corrections (1) fter 2 weeks, 2 visits, 3 syringes of 3ml (2) on-surgical facial contouring using a combination of the hyaluronic acid filler TESY (,, and ) by eaders Skin Group ak Kyung Rho. The linical Journal of the ssociation of Korean ermatologists Vol. 15 o. 4 VEMBER 2012 FTER (1)
Scientific art applied to volumising and contouring Volume recovery for wide areas Volume creation for targeted areas Malar rea Facial contour heekbones hin TEXE T SURE REF: 500219/01 EMHEU ESG SEPTEMBER 2013 H oncentration: 22 mg/m idocaine 0,3% () Box / eedle: / 27G ½ " 1 x 3 m / 23G 1 " H oncentration: 25 mg/m idocaine 0,3% () Box / eedle: / 25G 1 " 2 x 1.2 m / 25G 1 "